Keam Susan J
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Paediatr Drugs. 2024 Jan;26(1):95-100. doi: 10.1007/s40272-023-00600-y.
Cantharidin (YCANTH™) is a proprietary drug-device combination product containing a formulation of cantharidin 0.7% topical solution (a vesicant naturally derived from blister beetles) delivered via a single-use applicator that has been developed by Verrica Pharmaceuticals Inc. for the treatment of molluscum contagiosum and is also being developed for the treatment of warts. In July 2023, YCANTH™ (cantharidin 0.7% topical solution) was approved for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older in the USA. This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
斑蝥素（YCANTH™）是一种专利药物-器械组合产品，包含0.7%斑蝥素局部溶液制剂（一种天然来源于斑蝥的发泡剂），通过一次性涂抹器给药，由Verrica制药公司开发，用于治疗传染性软疣，也正在开发用于治疗疣。2023年7月，YCANTH™（0.7%斑蝥素局部溶液）在美国被批准用于2岁及以上成人和儿童患者传染性软疣的局部治疗。本文总结了0.7%斑蝥素局部溶液的研发历程，该溶液首次获批用于2岁及以上成人和儿童患者传染性软疣的局部治疗。
